Calvert A H
Cancer Research Unit, University of Newcastle upon Tyne, Medical School, England.
Anticancer Res. 1994 Nov-Dec;14(6A):2273-8.
Carboplatin haematological toxicities are clearly related to AUC. It seems likely that therapeutic efficacy is also related to AUC, although the maturation of clinical trials is necessary to establish this point. Using AUC-based dosing compensates for variations in renal function between and within individual patients. Since this variability is considerable, AUC-based dosing is a desirable practice. However, it does not allow for other factors such as previous chemotherapy, previous radiotherapy or performance status. Thus it does not remove the requirement for clinical judgements when managing a patient with cancer; it simply helps to remove one of the subjective elements of such judgements.
卡铂的血液学毒性显然与曲线下面积（AUC）相关。治疗效果似乎也与AUC有关，尽管需要临床试验的成熟来证实这一点。采用基于AUC的给药方案可补偿个体患者之间以及个体患者自身肾功能的差异。由于这种变异性相当大，基于AUC的给药是一种可取的做法。然而，它没有考虑其他因素，如既往化疗、既往放疗或体能状态。因此，在管理癌症患者时，它并不能消除临床判断的必要性；它只是有助于消除此类判断中的一个主观因素。
